Egyptian Rheumatology and Rehabilitation

ORIGINAL ARTICLE
Year
: 2015  |  Volume : 42  |  Issue : 3  |  Page : 153--158

Effect of chondroitin sulfate on cartilage volume loss and subchondral bone marrow lesions in osteoarthritis knee


Mohammad H Elgawish1, Mohammad A Zakaria2, Hadeer S Fahmy3, Anwar A Shalaby4 
1 Department of Physical Medicine, Rheumatology & Rehabilitation, Faculty of Medicine, Zagazig University, Zagazig, Egypt
2 Department of Physical Medicine, Rheumatology & Rehabilitation, Faculty of Medicine, Ain Shams University, Cairo, Egypt
3 Department of Radiodiagnosis, Faculty of Medicine, Zagazig University, Zagazig, Egypt
4 Department of Radiodiagnosis, Faculty of Medicine, Al-Azhar University (Cairo branch), Cairo, Egypt

Correspondence Address:
Mohammad A Zakaria
Department of Physical Medicine, Rheumatology & Rehabilitation, Faculty of Medicine, Ain Shams University, Cairo 30012
Egypt

Background Chondroitin sulfate (CS) is a major component of the extracellular matrix of many connective tissues, including cartilage, bone, skin, ligaments, and tendons. Objective The aim of this work was to study the effect of CS treatment for short time (6 months) clinically and using MRI on cartilage volume loss, subchondral bone marrow lesions (BMLs), and synovitis in patients with primary knee osteoarthritis (OA). Patients and methods A total of 50 patients with primary knee OA and clinical signs of synovitis were included in this study. They were divided into two treatment groups. Group 1 included 30 patients who received two capsules of CS (structum capsule 500 mg) once daily for 6 months. Group 2 included 20 patients who received placebo once daily for 6 months. Clinical, radiological, and laboratory assessments were performed for all patients. Cartilage volume loss, subchondral BMLs, and synovial membrane thickness were assessed with MRI at baseline and after 6 months for both groups. Results The CS group showed significantly less cartilage volume loss compared with the placebo group after 6 months for the global knee, lateral compartment and tibial plateaus. However, there were no significant differences in the medial compartment and trochlea between the two groups. Significantly lower BML scores were found for the CS group compared with the placebo group after 6 months, and there were no significant differences in synovial membrane thickness between the two groups. Disease symptoms were similar in both groups. Conclusion CS treatment significantly reduces the cartilage volume loss and subchondral BMLs in primary knee OA after 6 months of treatment. These findings suggested a joint structure-protective effect of CS.


How to cite this article:
Elgawish MH, Zakaria MA, Fahmy HS, Shalaby AA. Effect of chondroitin sulfate on cartilage volume loss and subchondral bone marrow lesions in osteoarthritis knee.Egypt Rheumatol Rehabil 2015;42:153-158


How to cite this URL:
Elgawish MH, Zakaria MA, Fahmy HS, Shalaby AA. Effect of chondroitin sulfate on cartilage volume loss and subchondral bone marrow lesions in osteoarthritis knee. Egypt Rheumatol Rehabil [serial online] 2015 [cited 2020 Dec 2 ];42:153-158
Available from: http://www.err.eg.net/article.asp?issn=1110-161X;year=2015;volume=42;issue=3;spage=153;epage=158;aulast=Elgawish;type=0